novel therapies in heart failure - university of groningen · 2016-06-16 · chapter 2 effects of...
TRANSCRIPT
University of Groningen
Novel therapies in heart failureLiu, Licette Cécile Yang
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.
Document VersionPublisher's PDF, also known as Version of record
Publication date:2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):Liu, L. C. Y. (2016). Novel therapies in heart failure. [Groningen]: Rijksuniversiteit Groningen.
CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.
Download date: 23-08-2020
Novel Therapies in Heart Failure
Licette C.Y. Liu
Licette Cécile Yang LiuNovel Therapies in Heart Failure
Copyright © 2016, Licette C.Y. LiuAll rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.
Layout and printed by: Optima Grafische Communicatie, Rotterdam, the NetherlandsCover design: Liza Renee - Illustratie & Vormgeving, Groningen, the Netherlands.
Financial support for the publication of this thesis by the following institutes or com-panies is gratefully acknowledged:
University of Groningen, Graduate School of Medical Sciences, Pfizer B.V., Biotronic Nederland B.V., Servier Nederland Farma B.V., Amgen B.V., Daiichi Sankyo Nederland B.V., ChipSoft B.V., Bayer B.V.
ISBN: 978-94-6169-895-7E-pub ISBN: 978-94-6169-898-8
Novel Therapies in Heart Failure
Proefschrift
ter verkrijging van de graad van doctor aan deRijksuniversiteit Groningen
op gezag van derector magnificus prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 29 juni 2016 om 14.30 uur
door
Licette Cécile Yang Liu
geboren op 25 februari 1988te Hoogezand-Sappemeer
PromotorProf. dr. A.A. Voors
CopromotorDr. P. van der Meer
BeoordelingscommissieProf. dr. W.H. van GilstProf. dr. P.A. de GraeffProf. dr. M. Metra
Paranimfen drs. A. Fluitman drs. M.A. de Vries
Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged.
To begin, beginWilliam Wordsworth (1770-1850)
TaBle oF CoNTeNTs
Introduction 13
Part I: Precision Medicine in Heart Failure
Chapter 1 A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine
33
Chapter 2 Effects of Serelaxin in Acute Heart Failure Patients with Renal Impairment: Results from RELAX-AHF
51
Chapter 3 Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT trial
71
Part II: Novel Drugs for the Treatment of Heart Failure with Preserved ejection Fraction
Chapter 4 Renal Effects of the Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Patients with Heart Failure and Preserved Ejection Fraction
103
Chapter 5 Effects of Sildenafil on Invasive Hemodynamics and Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction and Pulmonary Hypertension: A Randomized Controlled Trial
123
Chapter 6 Effects of Sildenafil on Cardiac Structure and Function, Cardiopulmonary Exercise Testing and Health-Related Quality-of-Life Measures in Heart Failure Patients with Preserved Ejection Fraction and Pulmonary Hypertension
153
Part III: Drug evaluations of Novel Drugs for the Treatment of Heart Failure with Reduced ejection Fraction
Chapter 7 Finerenone: Third Generation Mineralocorticoid Receptor Antagonist for the Treatment of Heart Failure and Diabetic Kidney Disease
179
Chapter 8 Omecamtiv Mecarbil: a Novel Cardiac Myosin Activator for the Treatment of Heart Failure
203
General Discussion and Future Directions 225
Nederlandse Samenvatting 245
Dankwoord 255
Curriculum Vitae 261
List of Publications 263